

FOR IMMEDIATE RELEASE



## Evaluation of MosaiQ™ Platform Chosen as a Top Poster at the AABB 2013 Annual Meeting

**NEWTOWN, PA., September 20, 2013** – Quotient Limited (“Quotient”), a supplier of innovative and high-quality transfusion diagnostic products to hospitals, blood banks and other healthcare institutions, is pleased to announce that the first publicly released data on its MosaiQ™ platform has been selected as a Top Poster at the AABB 2013 Annual Meeting, October 12-15 in Denver, CO. Less than 5% of the accepted posters have this designation.

*“The selection of our first abstract on the MosaiQ™ platform as a Top Poster at AABB is an honor, and we expect it to be the first of many accomplishments as we accelerate development of this novel, serology-based microarray platform”, said Ed Farrell, President and leader of the MosaiQ™ project. “We believe MosaiQ™ has the potential to significantly impact and improve how blood grouping is conducted, and this abstract is another step towards making MosaiQ™ a commercial reality.”*

The title of the abstract is “*Evaluation Of A Novel Serology-Based Platform for Irregular Blood Group Antibody Identification (Project MosaiQ™)*”, and outlines interim results of an antibody identification study that compares results from testing on the MosaiQ™ assay versus parallel testing on column agglutination and manual tube based methods. This data represents the first data publicly presented regarding the system. Another abstract describing the results of the MosaiQ™ antigen-typing program will also be presented at AABB.

MosaiQ™ is a proprietary, serologic, protein:protein microarray approach that combines novel nanoprinting techniques, surface chemistries, existing, well-characterized assays, and full walk-away, high-throughput instrumentation to allow laboratories to:

- Determine the full antigen profile of patient and donor red blood cells (“Antigen-Typing”)
- Identify antibodies in donor and patient plasma (“Antibody-ID”)
- Undertake full mandatory serological virology screening on donor blood (“Disease Screening”).

### About Quotient

Quotient is a transfusion diagnostics company with more than 30 years of product development, manufacturing, sales and distribution of immunohematology products worldwide. Quotient’s current business is focused on providing innovative, high-quality and cost effective manual reagents and controls to hospitals and blood centers worldwide.

Quotient is able to offer end users across the USA a comprehensive range of products, including:

- (i) **ABO Rh blood typing reagents** - Anti-A, Anti-B, Anti-AB and Anti-D;
- (ii) a range of **rare antisera products** - including Anti-E, Anti-c, Anti-k, Anti-M, Anti-N, Anti- Le<sup>a</sup>, Anti-Le<sup>b</sup>, Anti-Lu<sup>b</sup>; and now, Anti-s, Anti-Fy<sup>a</sup>, Anti-Fy<sup>b</sup>, Anti-Wr<sup>a</sup>, and Anti-K;

- (iii) the **ALBAcyte<sup>®</sup> range of reagent red blood cells** - including reverse cells, screening cells and both untreated and enzyme-treated identification panels;
- (iv) the **ALBAclone<sup>®</sup> Advanced Partial RhD Typing Kit** - which identifies weak and partial RhD types with results comparable to molecular analysis, but at a fraction of the cost;
- (v) the **ALBAcheck<sup>®</sup> Competency Training Kit** – a kit which incorporates masked, positive or negative antibody samples to train or assess staff on manual or gel testing; and
- (vi) **enhancement media** and other specialty products.

In addition to the above products, Quotient has nearly as many products in its development pipeline, either submitted to the FDA for licensing or in preparation for submission. The MosaiQ™ project represents the next step in the company's evolution.

For more details about the full range of products offered by Quotient in the USA, please visit our website [www.quotientbd.com](http://www.quotientbd.com).

###